RSV update 2011-2012 Chuck Hui MD FRCPC Pediatric Infectious Diseases Medical Director, RSV Prophylaxis clinic CHEO MOHLTC Ontario RSV Prophylaxis program.

Slides:



Advertisements
Similar presentations
Immunization and RSV/Palivizumab Clinic Update Advances in preventative care for our pediatric population.
Advertisements

A 23 year old business woman got two shots of hepatitis B 1 month apart 2 years ago. Today she is at your practice for ending the schedule. What should.
Sask BCG Discontinuation Dr. Ibrahim Khan Saskatchewan TB Education Day 28 th October, 2011.
Influenza Prevention We anticipate that there will be two types of influenza illness and two different types of influenza vaccine this year Seasonal influenza.
Chuck Hui MD FRCPC Paediatric Infectious Diseases Assistant Professor of Paediatrics Respiratory Syncytial Virus Prophylaxis
Perinatal Varicella By Rafat Mosalli MD FAAP FRCPC.
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
U.S. Surveillance Update Anthony Fiore, MD, MPH CAPT, USPHS Influenza Division National Center for Immunizations and Respiratory Disease Centers for Disease.
Bronchiolitis and Synagis. CONTINUITY CLINIC Pretest Which of the following children should receive RSV prophylaxis during RSV season? Which of the following.
Pandemic Influenza: Role and Responsibility of Local Public Health Richard M. Tooker, MD Chief Medical Officer Kalamazoo County Health and Community Services.
OHIP-Funded Physiotherapy in Long-Term Care Homes Prepared by: Provider Services Branch Health System Accountability and Performance Division Ministry.
Miriam Nuño Harvard School of Public Health, USA Gerardo Chowell Los Alamos National Laboratory, USA Abba Gumel University of Manitoba, Canada AIMS/DIMACS/SACEMA.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Nebulized Hypertonic Saline for Bronchiolitis Florin TA, Shaw KN, Kittick M, Yakscoe.
Basics: 2As & R Clinical Intervention Artwork by Nancy Z. © 2010 American Aca0emy of Pediatrics (AAP) Children's Art Contest. Support for the 2010 AAP.
Systematic Reviews and the American Academy of Pediatrics Virginia A. Moyer, MD, MPH Professor of Pediatrics Baylor College of Medicine.
Adult Immunization 2010 Influenza Segment This material is in the public domain This information is valid as of May 25, 2010.
Triage Nurse Initiation of Corticosteroids in Paediatric Asthma is Associated With Improved Emergency Department Efficiency Zemak et al Pediatrics Volume.
CONTRAST AGENTS AND RADIOPHARMACEUTICALS IN CHILDREN WITH CARDIAC DISEASE: SHOULD THEIR USE BE STUDIED? John C. Ring, MD, FAAP, FACC Associate Professor.
Washington State Hospital Association Medicaid Quality Incentive ER is for Emergencies Medicaid Quality Incentive ER is for Emergencies Web Conference.
Incidence of Influenza in Ontario Following the Universal Influenza Immunization Campaign Dianne Groll PhD, University of Ottawa David J Thomson PhD, Queen’s.
HealthSanté CanadaCanada Influenza Prevention and Control in Canada Arlene King, MD, MHSc, FRCPC Director, Immunization and Respiratory Infections Division,
Cost-Conscious Care Presentation Follow-up Chest X-Ray in Patients Admitted for Community Acquired Pneumonia Huy Tran, PGY-2 12/12/2013.
20 Answers About Influenza
Inputs to a case-based HIV surveillance system. Objectives  Review HIV case definitions  Understand clinical and immunologic staging  Identify the.
Memorial Hermann Healthcare System Clinical Integration & Disease Management Dan Wolterman April 15, 2010.
An International Case Study of Lung Transplantation
Facts about the Trust £110 million pound turnover 1,619 staff plus staff employed by contractors 33,365 inpatient and day cases were treated 10,670 elective.
1 Universal Immunization Against Rare Diseases  How much is a child’s life worth?  The individual vs society.
Respiratory Syncytial Virus Prophylaxis The criteria
Your Child's Best Shot A parent's guide to vaccination.
Pediatric Research in Office Settings (PROS). Introduction  Four million births each year in U.S.  Decreasing lengths of postpartum stay  Responsibility.
Palivizumab: a centralised clinic Laura Marshall RCN Conference 13 th March 2008.
The Variations and Deviations in the Use of Tympanostomy Tubes for Children with Otitis Media Salomeh Keyhani MD MPH Lawrence C. Kleinman MD MPH Michael.
Updated ACIP Recommendations for Using Hepatitis A Vaccine for Postexposure and International Travel Management Miriam J. Alter, Ph.D., MPH Infectious.
Insert Program or Hospital Logo Introduction The Respiratory Syncytial virus (RSV) was discovered in 1956 and has been since recognized as one of the most.
Learning from the 2009 H1N1 Pandemic Response 1 Daniel S. Miller MD, MPH Director, International Influenza Unit Office of the Secretary Office of Global.
Rangel PDSA TB Didactic TB or not TB?. AIM Statement In order to improve care at the Charles Rangel Clinic, we will implement a tuberculosis screening.
Immunoprophylaxis for Prevention of Severe RSV Bronchiolitis Ma. Teresa C. Ambat, MD Neonatology-TTUHSC11/21/2008.
Champlain Mental Health and Addictions Nurses (MHAN) working with OCDSB February 15, 2013 OCDSB PD Day.
Monthly Journal article review: Vimmi Kang PGY 2
Suttajit S a, Tantipidoke R a, Sitthi-amorn C a, Wagner A b, Ross-Degnan D b. a Chulalongkorn University, Bangkok; b Harvard Medical School, USA Problem.
Module 2 - Epidemiology of Tuberculosis
Age appears to be a significant effect modifier of the impact of palivizumab on RSV hospitalization risk. Given the rapid decrease of RSV risk with increasing.
Greg Rex Department of Pediatrics, Division of Allergy IWK Health Centre Immunology and Allergy Update.
RSV RT 265. Respiratory Syncytial Virus Manifests primarily as: Bronchiolitis Bronchiolitis Viral pneumonia Viral pneumonia Leading cause of lower respiratory.
1 Novel Influenza A H1N1 Outbreak: The Florida Response Epidemiology Perspective: Situation Update.
Chuck Hui MD FRCPC Paediatric Infectious Diseases Assistant Professor of Paediatrics Streamlining requests for RSV prophylaxis through the maze at CHEO.
Lung Volume Reduction Surgery and Quality of Life Amy Burker ALHE 4060/ Masini April 22, 2007.
Specialised Geriatric Services Heather Gilley Sharon Straus.
CDC Guidelines for Use of QuantiFERON ® -TB Gold Test Philip LoBue, MD Centers for Disease Control and Prevention Division of Tuberculosis Elimination.
1 Vaccines Contraindications. Contraindications to any routine active immunization procedure An acute febrile illness, malaise, cough, diarrhea, or other.
CURRENT HEALTH PROBLEMS IN STUDENT'S HOME SOUNTRIES HEPATITIS B IN MALAYSIA MOHD ZHARIF ABD HAMID AMINUDDIN BAKI AMRAN.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Intermittent vs Continuous Pulse Oximetry McCulloh R, Koster M, Ralston S, et al.
Recommendations for Postexposure Prophylaxis of Varicella Infection Mona Marin, MD Centers for Disease Control and Prevention Blood Products Advisory Committee.
Pediatricians, Medical Students and the Early Intervention System in Hawaii Marge Wada CCC-SLP State of Hawaii Early Intervention Programs Jeffrey Okamoto.
Bronchiolitis Abdullah M. Al-Olayan MBBS, SBP, ABP. Assistant Professor of Pediatrics. Pediatric Pulmonologist.
"Epidemiological Features of Rotavirus Infection among children below 5 years old in Jordan, Rationale for Vaccine Introduction,2015" Kareman Juma`ah Al-Zain.
Current Pandemic H1N1 Updates in the Philippines Department of Health, Philippines Juan M. Lopez, MD, PGradDipPH, MPH Aldrin Q. Reyes, RN.
Inpatient Palliative Care A hospital service at SOMC where patients can benefit from palliative care consultative services during their hospitalization.
Dr Karl Davis Consultant Geriatrician. Public Health Wales All the frameworks highlighted the following six areas as key priorities (although there is.
Using implementation science to improve child household contact screening for tuberculosis in Eldoret, Kenya: Overview and lessons learned Daria Szkwarko,
The Children’s Aid Society of Brant Preliminary Findings Crown Ward Review 2011 February 28-March 10, 2011.
SECONDARY PREVENTION IN HEART DISEASE CATHY QUICK AUBURN UNIVERSITY/AUBURN MONTGOMERY EBP III.
Introduction Extremely low birth weight (ELBW) infants are those with birth weight of
Burden of acute otitis media, recurrent otitis media and tympanostomy tube insertion in urban, minority children less than 7 years of age in Boston: Comparison.
IFSP Aligned with the Early Intervention Data System
Bronchiolitis Clinical Practice Guideline QI Project
RISK R isk of Perinatal and Early Childhood Infection
Provincial Measles Immunization Catch-Up Program
Presentation transcript:

RSV update Chuck Hui MD FRCPC Pediatric Infectious Diseases Medical Director, RSV Prophylaxis clinic CHEO MOHLTC Ontario RSV Prophylaxis program advisory group member

Conflict of Interest Declaration Local investigator on two investigator driven, Abbott funded trial Member of the Canadian Pediatric Society Infectious Diseases Immunization Committee, the Committee to Advise on Tropical Medicine and Travel, and the Ministry of Health and Long Term Care of Ontario RSV Advisory Group

Objectives Address the AAP and CPS guidelines Identify the underlying assumptions and reasoning for the guidelines Contrast the guidelines with the MOHLTC guideline To review the process for enrolling patients into the provincial RSV Prophylaxis for High-Risk Infants Program for the season To highlight changes to the enrolment form, enrolment process, drug ordering process and dosing schedule

What is RSV? RNA paramyxovirus –2 strains – A and B Often circulate concurrently Humans are only source Almost all children infected at least once by 2 yrs of age Re-infection is common Presents as a common URI in older children and adults

Epidemiology Annual season in Canada –November to April Viral shedding 3-8 days –May be longer in young and immunosuppressed Incubation period 2-8 days Supportive care, no good treatment

Burden of RSV in Young Children Population based study in children < 5yrs ER ( ); Pediatric offices ( ) 5067 enrolled; 919(18%) RSV infections; RSVH overall (11%) RSV associated with:18% ER visits 15% office visits Average RSVH: 17/1000 <6 months of age 3/1000 < 5 years of age Hall CB et al. NEJM 2009;360:

Burden of RSV in Young Children Majority of children had no underlying medical illness Only risk factors identified: < 2 years of age, history of prematurity Under 5 yrs of age RSV results in:  1 of 38 visits to the ER  1 of 13 visits to a primary care (FD) office Hall CB et al. NEJM 2009;360:

Global Burden Global burden of disease related to RSV in children younger than 5 years Systematic review –33.8 million new episodes of RSV-associated ALRI occurred worldwide in children younger than 5 years –3.4 million episodes representing severe RSV-associated ALRI necessitating hospital admission –66 000– children younger than 5 years died from RSV associated ALRI in % of these deaths occurring in developing countries Lancet May 1; 375(9725)

Treatment Does not work… –Bronchodilators –Steroids –Hypertonic saline –Physiotherapy –Montelukast –Antibiotics Cochrane Database Systematic Review Cochrane Database of Systematic Reviews Cochrane Database Systematic Reviews 2007 NEJM 357;4, July 26, 2007 NEJM 360;20 May 14, 2009 British Medical Journal 1966;1:83–5

Prevention - Palivizumab Efficacy IMPACT Pediatrics 1998

When we don’t have anything else, we have a bunch of grumpy old ‘experts’ sitting around a table…

American Academy of Pediatrics (AAP) Background Statements 1998, 2003, 2009 Significant geographic variability in the US Third party payers AAP recommendations are meant only for American Pediatricians

American Academy of Pediatrics (AAP) 2009 Congenital Heart Disease (CHD) and Chronic Lung Disease (CLD) Unchanged Dosing maximal number of 5 doses for all geographic locations for infants with hemodynamically significant CHD, CLD, or birth before 32 weeks' 0 days' gestation maximal number of 3 doses for infants with a gestational age of 32 weeks 0 days to 34 weeks 6 days without hemodynamically significant CHD or CLD

American Academy of Pediatrics (AAP) to 34 6 Risk factors: –infant attends child care; or –1 or more siblings or other children younger than 5 years live permanently in the child's household Infants with a gestational age of 32 weeks 0 days through 34 weeks 6 days born within 3 months before the start of RSV season or at any time throughout the RSV season will qualify for prophylaxis under the new recommendations if they have at least 1 of these 2 risk factors. Previous recommendations required 2 of 5 risk factors Infants born from 32 weeks' 0 days' through 34 weeks' 6 days' gestation who qualify for prophylaxis under the new recommendations should receive prophylaxis only until they reach 90 days of age or a maximum of 3 doses (whichever comes first). This is a change from the previous recommendation for 5 months of prophylaxis

Risk factors for RSV hospitalization worldwide Exposure Age at start of RSV season Siblings Crowding at home Day care attendance Day care attendance of siblings Discharge between October and December Social Factors Breast feeding Physiologic Factors Low birth weight Male sex Family history of wheezing CLD Neurologic problems Birth order >2 nd Eur J Clin Microbiol Infect Dis (2008) 27:891–899

Variables in the final Logistic Regression Model (Risk Scoring Tool- PICNIC Study) Variable Score SGA (GA <10%)[ Yes/No ]12 Gender (Male/Female)11 Birth Month (Nov,Dec,Jan)25 Subject or Siblings in Day Care [ Yes/No ]17 Family History without eczema [ Yes/No ]12 >5 individuals in the home counting the subject [ Yes/No ]13 Two or more smokers in the house [Yes/No ]10 Total100

Only 3 doses? McCormick J, Pediatr Pulmonol. 2002;34:

Canadian Paediatric Society (CPS) Background Previous position statements 1999, 2003, 2009 Updated 2011 GRADE evidence based assessment Cost-effectiveness assessment

Canadian Paediatric Society (CPS) 2011 Congenital Heart Disease (CHD) and Chronic Lung Disease (CLD) Criteria – unchanged Recommendation –receive up to five doses of palivizumab (strong recommendation/high-quality evidence) Remarks - Decisions regarding the use of palivizumab in this and all other high-risk groups need to take competing local priorities for funding into account, which may allow for use of palivizumab in only selected infants in this cohort Values and preferences - This recommendation places a high value on preventing hospitalizations in these vulnerable infants despite the high cost of palivizumab

Canadian Paediatric Society (CPS) 2011 Infants in remote communities who would require air transportation for hospitalization: Recommendation #1 –Consideration should be given to administering up to five doses of palivizumab for all infants born before 36 weeks’ GA and younger than six months of age at the beginning of the RSV season (strong recommendation/high-quality evidence). Remarks. It is not clear whether this recommendation should apply only to Inuit infants, to all Aboriginal infants or to all infants in remote communities. The incidence of RSV hospitalization in a remote community in previous years should be taken into account when making this decision. A practical issue is that the onset and duration of RSV season is unpredictable in the Far North. Occasionally, more than a year goes by between RSV seasons (Michael Young, personal communication). To save money, one would delay administering palivizumab until there is confirmed RSV activity in a remote community. The attendant risk is that significant spread may have already occurred. Values and preferences. This recommendation places high value on preventing RSV hospitalizations because of the high cost of such admissions.

Canadian Paediatric Society (CPS) 2011 Recommendation #2 –Consideration may be given to administering up to five doses of palivizumab to term Inuit infants younger than six months of age in communities with documented persistent high rates of RSV hospitalizations (weak recommendation/no evidence) Remarks. There is no direct evidence of the efficacy of palivizumab in term Inuit infants, but observational studies in preterm Inuit infants and in term infants with other risk factors suggest that there would be efficacy. There are insufficient data regarding the morbidity from RSV to recommend use in term infants in other Northern populations

Canadian Paediatric Society (CPS) weeks 0 days to 35 weeks 6 days’ GA: Recommendation #1 –A panel of experts should be convened in each province or territory (weak recommendation/no evidence) to establish a policy for these infants Remarks - The upper limit of GA may need to be determined by available funding Recommendation #2 –The panel may want to use the American Academy of Paediatrics (AAP) criteria, or the Canadian risk-scoring tool, to select infants eligible for palivizumab prophylaxis (weak recommendation/no evidence) Remarks. It seems likely that applying the AAP criteria would result in more infants being prophylaxed, but for a shorter time. It is impossible to predict the relative impact on hospitalizations

Canadian Paediatric Society (CPS) 2011 Recommendation #3 –Irrespective of the criteria chosen, giving the last dose at three months’ chronological age should be considered in this GA cohort (weak recommendation/no evidence) Remarks. This recommendation is an attempt to balance cost and benefit, and is designed to protect infants at greatest risk of hospitalization

Canadian Paediatric Society (CPS) 2011 Immunodeficiencies, Down syndrome, cystic fibrosis, upper airway obstruction or a chronic pulmonary disease other than CLD: Recommendation –Palivizumab is not routinely recommended. However, it may be considered for children younger than 24 months of age (because they may not yet have encountered their first RSV infection) who are likely to be exposed to RSV and are on home oxygen, have had a prolonged hospitalization for severe pulmonary disease, or are severely immunocompromised (weak recommendation/no evidence) Remarks. This recommendation should be expanded to include more children with pulmonary disease if evidence becomes available that avoidance or delay of the initial RSV hospitalization impacts long-term pulmonary function How should palivizumab be administered? Recommendation –Each jurisdiction should optimize processes to implement these recommendations in the most cost- effective manner. Well-organized palivizumab clinics decrease drug wastage (strong recommendation/no evidence)

OK, tell me what I need to know!!!!!!

MOHLTC Ontario Background Administered through the Exceptional Access Program (EAP) MOH RSV Advisory Group RSV Adjudicators

MOHLTC Ontario Background Administered through the Exceptional Access Program (EAP) MOH RSV Advisory Group RSV Adjudicators NO CHANGE!

MOHLTC Ontario Prematurity ≤ 32 completed weeks gestation and aged ≤ 6 months at the start of, or during, the local RSV season; or 33 – 35 completed weeks gestation and aged ≤ 6 months at the start of, or during the local RSV season, who DO NOT live in isolated communities AND have a Risk Assessment Tool Score of 49 to 100; or 33 – 35 completed weeks gestation and aged ≤ 6 months at the start of, or during the local RSV season, and who LIVE IN isolated communities where paediatric hospital care is not readily accessible and ambulance transportation for hospital admission is required;

MOHLTC Ontario CHD/BPD/Down Syndrome < 24 months of age with Down Syndrome / Trisomy 21; or < 24 months of age with BPD/CLD and who required oxygen and/or medical therapy within the 6 months preceding the RSV season; or < 24 months of age with hemodynamically significant (HS) cyanotic or acyanotic congenital heart disease (CHD); requiring corrective surgery or is on cardiac medication for hemodynamic significant disease

MOHLTC Ontario Special Requests Assessed on an individual basis Requires letter from requesting physician and an ID + Respirologist signature Potential diagnoses: –Upper airway anomalies, severe immunodeficiencies, neuromuscular diseases, etc.

START: Ontario RSV Medical Advisory Group has recommended November 14 th, 2011 as season start END: April 1 st, 2012 or when season is declared ended locally, whichever comes first Season is considered on-going when there are 2 or more local RSV hospitalizations / week for two consecutive weeks SEASON START / END

Out of season process From May 1 st – November 1 st, 2011 NICUs identify patients that qualify for prophylaxis in a log book and send the referrals to CHEO RSV Coordinator monthly Enrolment forms / appointment arrangements completed by CHEO RSV Coordinator

During season (November – March) NICUs enroll their own patients with Abbott First dose of Synagis  is administered prior to discharge from NICU Follow up appointments may be made by NICUs by directly contacting CHEO’s Ambulatory Care Call Center ( ) NICUs fax / Abbott reference no. and patient info to CHEO RSV Coordinator

Summary of Changes: Enrolment process 2.Enrolment forms 3.Drug ordering process 4.Dosing schedule

ENROLMENT PROCESS All enrolments will now be processed and reference numbers provided by Abbott The ministry’s coordinator will review all those with BPD/CHD criteria and the special requests Enrolment forms are faxed directly to the Synagis  Coordinator at Abbott Canada ( )

ENROLMENT Turn around time is usually one business day (prematurity criteria) For enrolments under the BPD / CLD and CHD criteria and Special Requests, turn around time is three business days

ENROLMENT FORMS Since the form is now going to Abbott Canada and not MOHLTC, NO personal health identifiers (name, address, OHIP no.) are to be provided Fields for the child’s full name and OHIP no. have been removed from the enrolment forms Really simplified – one form for all Risk Assessment Tool is now part of the enrolment form on page 2

DRUG ORDERING PROCESS Shipment orders directed to Synagis  Coordinator at Abbott (fax: ) For NICUs who will give the first dose in November, it can be ordered using enrolment form (Section 7) All subsequent doses should be ordered on Synagis  order form Shipments occur within 24 hours, except for orders placed on Fridays, weekends and stat holidays

The ministry requests that all providers be mindful of costs such that drug wastage is minimized When an entire vial is not required for a patient, residual product may be used for a second patient if administered within 6 hours from the time of reconstitution under controlled and aseptic conditions $ $1,504.51

DOSING SCHEDULE (as per Ontario’s RSV Medical Advisory Group DoseWeek #Month 10Mid-November 23December 37January 411February 515March

ENROLMENT FORMS (on line) am/drugs/funded_drug/fund_respiratory.aspx

CHEO RSV Clinic Fridays (primarily) in clinic C1 on the main floor of CHEO First clinic: November 18, 2011 Team for the season: Josée Chiasson, RPN Chantal Horth, RC Carolyn Lawrence, RN Joanne Matton, PSC / Alyssa Long, PSC Barbara Murchison, RC Allyson Shephard, RN Chuck Hui, MD (Medical Director) Lisa Nesbitt (Clinical Manager)

CONTACT US By By telephone: Ext 2406 (Coordinator) By fax: